Explore Our Human Cord Blood Product Portfolio
Our human cord blood product portfolio includes fresh unprocessed cord blood and cryopreserved CD34+ hematopoietic stem and progenitor cells (HSPCs). Fresh unprocessed cord blood is available either as 0.5 – 1 billion total nucleated cells (TNC) units or > 1 billion TNC units. Cord blood-derived CD34+ stem cells are available in three different cryopreserved vialing formats including 100K and 500K cells/vial, as well as 1M cells/vial. The cord blood is collected aseptically at the time of delivery from healthy pregnant women who have consented under an IRB-approved protocol.
Umbilical cord blood is known to be a rich source of the most primitive type of CD34+ stem cells and which can be easily isolated using positive immunomagnetic cell separation procedures. In general, CD34+ stem cells comprise between 0.2 and 0.5% of total nucleated cells in cord blood units. CD34+ hematopoietic stem cells can be used for the development of cell-based therapies, regenerative medicine studies, or with humanized mouse models for oncology research. In addition to cord blood-derived CD34+ stem cells, we also offer CD34+ HSPCs isolated from mobilized leukopaks or bone marrow.
Evaluating Human Cord Blood as a Stem Cell Rich Source
Cord blood stem cells can differentiate into every type of cell in the blood including white blood cells, red blood cells, and platelets, making them valuable research tools across the research and therapy development spectrum. Umbilical cord stem cells are widely used in studies examining normal human development, in drug discovery, and in cell replacement and cell repair therapies. Cord blood products are also used in studies investigating cancers, anemias, immune system problems, and brain and spinal cord injuries. Cord blood is relatively rich in CD34+ stem cells, simple to collect, and can allow for less stringent HLA matching criteria in clinical applications due to the presence of more primitive stem cell types compared to those found in bone marrow or mobilized peripheral blood.
Lineage of CD34+ Hematopoietic Stem and Progenitor Cells (HSPCs)
Receive a complimentary poster to access information on immune cell markers, differentiation factors, cytokines, technical protocols, media recommendations, how-to videos, and more.
Due to sourcing issues, however, cord blood has limited availability compared to bone marrow or mobilized peripheral blood with no potential for donor recallability. This can lead to inconsistencies in the HPSC profile from collection to collection of cord blood, making it more difficult for use for cell therapy development. While CD34+ stem cells derived from cord blood have greater plasticity than hematopoietic stem and progenitor cells derived from other sources, they tend to have lower CD34+ stem cell total yields and thus may not be suitable for some applications.
Fresh Cord Blood Specifications
| Collection Volume Per Cord Blood Unit | % CD34+ Stem Cells Per Cord Blood Unit | CD34+ Stem Cell Total Yields Per Cord Blood Unit | Graft–Versus–Host-Disease Risk | Donor Recallability |
| 60 – 80ml | 0.2 – 0.5% of total nucleated cells | 1 – 3 million cells | low risk | not possible |